A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.
LATITUDE is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the AIDS Clinical Trials Group (ACTG), with additional support from the National Institute of Mental Health, the National Institute on Drug Abuse, ViiV Healthcare and the Janssen Pharmaceutical Companies of Johnson & Johnson.
“Antiretroviral therapy has been transformative in the treatment of HIV. Consistently taking these medications as prescribed helps people to live longer, healthier lives and prevents HIV transmission to sexual partners,” said Anthony S. Fauci, M.D., NIAID Director. “Unfortunately, for many people who must take any medication regularly, adherence can be difficult, Effective alternative formulations of antiretrovirals, including long-acting injectables, may help people better adapt to HIV treatment.”
LATITUDE will test two experimental, long-acting injections of the antiretroviral drugs rilpivirine (RPV) and cabotegravir (CAB), which will be administered every 4 weeks by a health care professional in a research clinic. Throughout the study, investigators will evaluate volunteers’ viral load—the measure of virus in the blood—and other indicators of immune health to compare the treatment’s effectiveness to that of conventional oral ART.
Up to a quarter of people prescribed conventional ART stop taking the medication for some period. Not taking ART as prescribed is the most common reason people do not achieve durable viral suppression. Many complex factors such as access to health care, economic and housing insecurity and stigma may influence a person’s ability to adhere to a treatment regimen. Long-acting ART formulations may particularly benefit those who cannot or would prefer not to take medication each day or to not keep oral medications in their home or possession.
